CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Life Science advisors

Atessia

The French version of the former anti-gift law

Atessia

Atessia

France is known for its strict regulatory provisions when it comes to medicines. The exception will not be made for the framework of relations between industries and health professionals, now known in France as the LEA. (anti-gift law)


So who is LEA?


Before, we used to say “anti-corruption law”, “DMOS”, “anti-gifts law”… These terms are no longer used. This system, which will soon celebrate its 30th anniversary (we are getting on in years), has just been revamped and we now speak of the “Benefits Framework System” or the “Benefits Framework Law” (the famous LEA in French) because it is a set of texts and a real arsenal put in place since October, 1st 2020 so that the State can better control relations between the health industries in particular, and health professionals in the broadest sense of the term. It should be remembered that it has to be considered in a very distinct way from the system of transparency of links, which pursues the objectives of publicising the advantages procured and agreements made in order to inform the general public and avoid any conflict of interest.


As we have just said, this system is not recent. It is true that over the years it has been considerably strengthened since it now concerns all health products, whether reimbursable or not, and its scope of application has gradually been extended to health professionals, students and their associations. But, in fine, its fundamental principle has remained the same: we are faced with a genuine “anti-corruption” mechanism applicable to relations between companies that market health products, such as medicines or medical devices, or provide health services, and health professionals (doctors, but also all other health professionals as well as osteopaths, chiropractors and psychotherapists). The aim is to ensure that HCPs are guided only by medical considerations in their choice of prescribing a product or health service and to prevent conflicts of interest.


More concretely, the general principle is the following:


• Prohibition for companies to provide health services, producing or marketing health products to grant direct or indirect benefits, in kind or in cash; and


• Prohibition on health professionals, associations of health professionals and civil servants/public officials covered by the scheme from receiving such benefits.


It should be noted that these prohibitions are punishable under criminal law and that there is joint responsibility between the companies granting undue advantages and the beneficiaries of these advantages


But let’s make it a little more complex… The LEA provides derogations from this principle of prohibition and subjects all authorised interactions (remuneration, hospitality in the context of professional, scientific or promotional events, participation in research activities, provision of services, sponsorship, donations) to prior control by the competent authorities, i.e. the medical professions’ council of order where they exist or the Regional Health Agency. However, one condition for the implementation of these derogations is the establishment of an agreement working as a contract which will then be submitted to the competent authorities. These derogations should not be confused with items excluded from the definition of a prohibited benefit, such as benefits in cash or in kind that relate to the exercise of the beneficiary’s profession and benefits of negligible value (e.g. impromptu meals, samples, books). It should be remembered that any benefit in excess of 10 euros must also be declared on https://www.transparence.sante.gouv.fr/ as part of the transparency of links.


Two submission regimes are possible: submission for declaration OR for authorisation.


To guide us in the choice of the applicable submission regime, threshold values have been published by decree. These values are then defined for each type of benefit provided. It now remains up to you to define the category in which your benefit falls…


If the benefits granted are below the thresholds, a declaration must be made 8 days before the benefit is granted, either on Idahe 2 or EPS. The benefit cannot be implemented before this deadline.


If the benefits granted are above the thresholds, an application for authorisation must be made at least two months before implementation. At the end of the two months, the competent authority will issue a binding decision, not an opinion.


To sum up :


Few innovations have been published since the new system was introduced on October 1st 2020, but the day-to-day implementation of the system raises a large number of questions of interpretation. ATESSIA can assist you in setting up and adapting your processes to comply with this system.


Reach out to ATESSIA: https://www.atessia.fr/fr/accueil/


Contact: Géraldine BAUDOT-VISSER


Email:hello@atessia.fr


Phone: +33 764 273 693


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://packaging.lifesciencesreview.com/leadership-perspective/the-french-version-of-the-former-antigift-law-nwid-1428.html